RT @synovialjoints: Bimekizumab (BKZ) in AxSpA to Wk52 ⦠sustained efficacy ⦠suppression of inflammation ⦠impr
Tweet Content
Bimekizumab (BKZ) in AxSpA to Wk52
◦ sustained efficacy
◦ suppression of inflammation
◦ improvements in function and quality of life
◦ no new safety signals were observed
◦ consistent with the safety profileWk24 data
Baraliakos #L14 https://t.co/gk23g4vqQl #ACR22 @RheumNow
Links
Bimekizumab Maintains Improvements in Efficacy Endpoints and Has a Consistent S…
http://bit.ly/3O6C3od
Show on Archive Page
On
Display in Search Results
On
PDQ
Off